C106 / Vicore Pharma - LARVOL DELTA

First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects (clinicaltrials.gov) - P1 | N=80 | Completed | Sponsor: Vicore Pharma AB | Recruiting ➔ Completed

Trial completion • Cardiovascular • Fibrosis • Hypertension • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Vicore provides update regarding Phase 1 study of C106 (Vicore Pharma Press Release) - P1 | N=72 | NCT05427253 | Sponsor:Vicore Pharma AB | "Vicore Pharma Holding AB...announced today that the Phase 1 study of C106 has concluded and that Vicore will not continue further development due to a transient increase in blood pressure observed at doses believed to be in the clinically effective range."

Discontinued • P1 data • Idiopathic Pulmonary Fibrosis • Respiratory Diseases

Development of Angiotensin II Type 2 Receptor Agonists 'ATRAGs' for Treatment of Pulmonary Fibrosis and Pulmonary Hypertension (ATS 2023) - "Methods and Results 1) Using receptor autoradiography, low concentations of C21 bind specifically to human lung tissue sections, and both C21 and the new ATRAG C106 (but not the AT1R antagonist valsartan) potently and dose-dependently displace Ang II binding in the lung sections; 2) In co-cultures of human primary airway epithelial cells + lung fibroblasts, C21 dose-dependently decreased myofibroblast activation marker α-Smooth Muscle Actin and fibrosis marker Collagen 1a1; 3) In precision cut human IPF lung slices, both C21 and C106 dose-dependently reduced spontaneous release of Transforming Growth Factor-β1 and Collagen 1a1; 4) In the rat Sugen-hypoxia PH model, oral C21 significantly reduced vascular remodeling and pulmonary artery pressure and improved hemodynamics. Conclusions Our data suggest that AT2R dominates over AT1R in the human lung and that ATRAGs represent a promising new drug class for treatment of diseases such as IPF and PH."

Cardiovascular • Fibrosis • Hypertension • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • TGFB1

First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Vicore Pharma AB | Trial completion date: Dec 2022 ➔ Jul 2023 | Trial primary completion date: Dec 2022 ➔ Jun 2023

Trial completion date • Trial primary completion date • Cardiovascular • Fibrosis • Hypertension • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Vicore Pharma AB

New P1 trial • Cardiovascular • Fibrosis • Hypertension • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases